HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $60 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 90.1%

Neg 0% Neu 90.1% Pos 0%

HC Wainwright & Co. analyst Joseph Pantginis reiterates Capricor Therapeutics (NASDAQ:CAPR) with a Buy and maintains $60 price target.